The problem remains unresolved with biologic DMARDs, including the tumor necrosis factor α (TNFα)–blocking class of proteins, which have been established as a standard in the treatment of RA in patients whose disease has failed to respond to conventional DMARDs (1). This evidence concerns the gene TNF and rheumatoid arthritis.